for eMaxHealth
In a press release issued today, Pfizer Inc announced the discontinuation of one of its Phase 3 studies (SUN 1107) using Sutent (sunitinib malate) in advanced breast cancer.
The SUN 1107 trial was designed to evaluated single-agent sunitinib versus single-agent capecitabine (Xeloda) for the treatment of advanced breast cancer after the patients failed standard treatment. The trial was stopped because Sutent was noted to not work better than capecitabine. Pfizer said five other studies looking at Sutent in advanced breast cancer will be continuing.
Sunitinib is currently approved for both gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, and advanced / metastatic renal cell carcinoma (RCC).
The role of sunitinib in the treatment of various other solid tumors including advanced non-small cell lung cancer, advanced colorectal cancer, advanced hepatocellular carcinoma and advanced hormone-refractory prostate cancer are being studied in Phase 3 trials.
Healthcare professionals who are interested in learning more about sunitinib trials that are open for enrollment can visit the SUN program web site at www.suntrials.com. Patients with questions should contact their treating physician.
Source
Pfizer Press Release
eMaxHealth welcomes your comments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
